Biomerica, Inc. (BMRA)
Pre-market:
| Previous close | 0.5960 |
| Open | 0.5610 |
| Bid | 0.6181 x 100 |
| Ask | 0.6400 x 100 |
| Day's range | 0.5610 - 0.6400 |
| 52-week range | 0.5000 - 2.1300 |
| Volume | |
| Avg. volume | 207,798 |
| Market cap | 10.599M |
| Beta (5Y monthly) | -1.04 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3700 |
| Earnings date | 15 Apr 2024 - 20 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireBiomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement
Dubai Healthcare Authority Granted Insurance Reimbursement for Biomerica’s EZ Detect™ Colon Disease Screening Test EZ Detect™ is a simple FDA cleared 2-minute at-home test that detects early warning signs of colorectal cancer, the third most common cancer worldwideAware® is an FDA cleared simple at-home device clinically tested to increase sensitivity in breast self-exams; about 80% of breast cancers are detected by women themselves noticing changes in their breastsFirst order placed for both Co
- GlobeNewswire
Biomerica provides update on inFoods® IBS expansion
- Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas. - Average quarterly increase in physicians prescribing inFoods more than doubled each quarter over the past 12 months. - Biomerica in discussions for launch of inFoods IBS with large non-GI physician groups opening new market for the product. - Company receives notice of allowance for five new patents in Europe, Canada and Japan; the inFoods technology now has 25 Issue
- GlobeNewswire
Biomerica Reports Third Quarter 2024 Financial Results
Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27 from $0.40 Amidst Sales Force Expansion for the Nine Months in Fiscal 2024 InFoods IBS Positive Clinical Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference in the DDW Irritable Bowel Syndrome (IBS) Clinical Session Company in discussions with Key Clinical Lab Customers for Use of its Recently US FDA 510(k) Cleared Hp Detect™ Test Product, Designed to Detect the Presence of the H. pylori Bacte
